Nosis Bio
Nosis Biosciences is a biotechnology company focused on revolutionizing RNA medicines by addressing the critical challenge of cell-specific delivery. Their proprietary platform, Connexa, leverages AI-powered drug design, single-cell biology, and high-throughput chemistry to create RNA therapeutics capable of targeting any cell type. This platform enables the silencing of disease-causing genes with improved efficacy, safety, and convenience, including redosable, long-duration subcutaneous administration. Nosis partners with pharmaceutical companies to develop these advanced RNA medicines for a range of chronic diseases, demonstrating traction through collaborations with major players like Daiichi Sankyo and Johnson & Johnson.
Nosis Bio
Nosis Biosciences is a biotechnology company focused on revolutionizing RNA medicines by addressing the critical challenge of cell-specific delivery. Their proprietary platform, Connexa, leverages AI-powered drug design, single-cell biology, and high-throughput chemistry to create RNA therapeutics capable of targeting any cell type. This platform enables the silencing of disease-causing genes with improved efficacy, safety, and convenience, including redosable, long-duration subcutaneous administration. Nosis partners with pharmaceutical companies to develop these advanced RNA medicines for a range of chronic diseases, demonstrating traction through collaborations with major players like Daiichi Sankyo and Johnson & Johnson.